Copyright ę 2009 Morningstar. All Rights Reserved. The information, data and opinions expressed (ôInformationö) and contained herein: (1) are proprietary to Morningstar and/or its content providers and are not intended to represent investment advice or recommendation to buy or sell any security; (2) may not be copied or distributed without express license to do so; and (3) are not warranted to be accurate, complete or timely. Morningstar reserve its rights to charge for access to these Ratings and/or Rating report. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this Rating, Rating Report or Information contained therein.
Merck in trattative avanzate per acquisizione Seagen da quasi 40 mld dollari - WSJ